Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

Researcher receives $2.7 million grant to study lingering Lyme disease symptoms

An estimated 1,200 Americans, on average, are diagnosed with Lyme disease each day. Some of those patients continue to experience negative effects, even after treatment.

14 Jul 2023

COVID antiviral treatments underused in nursing homes, study finds

Nursing homes were a key battleground during the COVID pandemic and prioritized for distribution of PPE, vaccines, and COVID testing kits.

14 Jul 2023

New drug could overcome resistance to CDK4/6 inhibitors in breast cancer

Brest cancer is the most common cancer in women. Among breast tumors that spread to other organs (develop metastasis), 70% belong to a variant, called luminal, whose cells are sensitive to the female sex hormones estrogen and progesterone. In fact, the tumor forms when these hormones order the cells to divide.

14 Jul 2023

Difficult transmembrane protein targets for therapeutic antibodies

In this interview, News-Medical talks to Sylvia Xie, product scientist at Sino Biological, about the ongoing emergence of transmembrane proteins as targets for therapeutic antibodies.

From Sino Biological Inc. 12 Jul 2023

AGS supports CMS decision to require registry data for monoclonal antibodies for Alzheimer's disease

The American Geriatrics Society (AGS) supports the recently announced decision from the Centers for Medicare and Medicaid Services (CMS) to require the collection of real-world information via a registry to study monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease.

11 Jul 2023

mAb-based bELISA developed to detect SARS-CoV-2 antibodies in a broad spectrum of animal species

Researchers developed a mAb-based blocking enzyme-linked immunosorbent assay (bELISA) to detect SARS-CoV-2 in animals.

11 Jul 2023

Scientists develop cross-species coronavirus test

In an advance that will help scientists track coronavirus variants in wild and domesticated animals, researchers report they can now detect exposure to the SARS-CoV-2 virus in any animal species.

6 Jul 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Understanding the biological effects of SARS-CoV-2 persistence in children

Researchers analyzed the most recent knowledge about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Jun 2023

New study offers clues on how to future-proof covid-19 vaccines

New research examining how frequently our bodies produce broadly neutralizing antibodies (bnAbs) capable of thwarting a range of SARS-CoV-2 variants offers clues on the strategy tweaks that could potentially future-proof COVID-19 vaccines.

26 Jun 2023

Viral clearance: A potential predictor of COVID-19 treatment efficacy

Researchers determine the virological effects of COVID-19 treatment and its clinical efficacy in the same trial.

22 Jun 2023

Treatment with dupilumab leads to sustained improvements in COPD patients with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.

20 Jun 2023

Battle against RSV: Computational design paves way for new polyvalent vaccine

Research focuses on the design of a multi-epitope polyvalent vaccine against Human Respiratory Syncytial Virus (RSV), a leading cause of lower respiratory tract infections. The study utilizes computational methods and immunoinformatics tools to predict potential vaccine candidates and their interactions with Toll-like receptors (TLRs).

19 Jun 2023

Broader search needed for successful management of eosinophilic gastritis

The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with eosinophilic gastritis.

16 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Study shows how blood makes the brain’s immune cells toxic

In patients with neurological diseases like Alzheimer's disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment.

8 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

MFAP5, a microfibril-associated protein, unveiled as key player in scar formation and wound healing

MFAP5, a microfibril-associated protein, plays a significant role in wound healing by regulating fibroblast function, collagen deposition, and angiogenesis, suggesting its potential as a modulator of scar formation.

1 Jun 2023